COMMUNIQUÉS West-GlobeNewswire

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
11/08/2026
The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter Presented preclinical data demonstrating differentiated [...]
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
11/08/2026
BETHESDA, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
11/08/2026
Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination study of [...]
Modern Haus Dental's Dr. Kristy Lee Recognized as Top Dentist by Bethesda Magazine for Third Consecutive Year
11/08/2026
She has also been named a Top Dentist by Washingtonian Magazine for two consecutive years Modern Haus Dental's Dr. Kristy Lee Earns Third Consecutive Bethesda Magazine Title Chevy Chase, MARYLAND, Aug. 11, 2026 (GLOBE [...]
AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
11/08/2026
AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD) Ongoing Phase 2 VacSYn study to expand to sites in USA with Investigational [...]
Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
11/08/2026
~ 2026 Second Quarter Net Product Sales of $17.1 Million, Up 78% Year over Year ~ ~ 2026 Second Quarter Non-GAAP Adjusted EBITDA of $2.8 Million ~ ~ Record PEDMARK ® Demand Carried into Third Quarter 2026 as Field Sales [...]
NeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue Growth
11/08/2026
Conference call will be held today, Tuesday, August 11 at 9:00 am ET CARMEL, Ind., Aug. 11, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company [...]
Constant Therapy Health Launches Web Platform for Speech, Language, and Cognitive Therapy
11/08/2026
Gives convenient desktop and laptop access to Constant Therapy’s clinically-proven rehabilitation exercise programs LEXINGTON, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Constant Therapy Health, a leader in AI-powered [...]
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma
11/08/2026
Selected 0.60 mg/m 2 as the single dose for the TeLuRide-006 study going forward for patients randomized to EIK1001 treatment, in accord with a recommendation of the independent Data Monitoring Committee (DMC) following [...]
Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
11/08/2026
Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. on track to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Secured equity [...]
Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth
11/08/2026
President & Chief Operating Officer Ryan Cohlhepp, Pharm.D. appointed President & Chief Executive Officer effective January 2027 Claire Mazumdar, Ph.D., MBA to transition to Vice Chair of the Board of Directors [...]
Arch Biopartners to Expand Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial to the United States
11/08/2026
TORONTO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (TSX Venture: ARCH and OTCQB: ACHFF) today announced that the Company will expand its ongoing Phase II trial of LSALT peptide targeting cardiac surgery- [...]
Neuronetics Reports Second Quarter 2026 Financial and Operating Results
11/08/2026
MALVERN, Pa., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient [...]
YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
11/08/2026
Two chrono-nutrition formulations — a daytime lipid-soluble “Golden Triangle” formula and a nighttime zinc-plus-calcium formula — were developed in collaboration with the Taiwan CDHA and FHI. The Company intends to [...]
IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update
11/08/2026
IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Phase 3 OVATION 3 [...]
Gibson Oncology Announces First Patient Completes Initial Treatment Cycle in Phase II Trial of LMP744 for Recurrent Glioblastoma
11/08/2026
Novel Blood-Brain-Barrier-Penetrant Agent Being Evaluated as a Single Therapy in a Trial Conducted by the National Institute of Neurological Disorders and Stroke (NINDS) MIAMI, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Gibson [...]
Noah Medical Announces Galaxy™ II, the Next Dimension in Robotic-Assisted Bronchoscopy
11/08/2026
New functionality gives physicians the freedom to choose the right imaging for every case and a more responsive drive experience without adding capital, complexity, or radiation SAN JOSE, Calif., Aug. 11, 2026 (GLOBE [...]
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
11/08/2026
Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026 The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high- [...]
NovelMed Advances Its Ocular Program, Highlighting the Potential of a Single Therapy Across Multiple Retinal Diseases
11/08/2026
--- A Versatile Complement Therapy Across Ocular, Hematologic, Renal, Dermatological, and Inflammatory Disorders. Key Highlights Commercial Precedent for One Molecule, Two Diseases : Biogen’s $5.6 billion acquisition of [...]

Pages